688062 Mabwell
- 22.95
- -0.26-1.12%
Mabwell News
Maiwei Biotech: Miwei Biotech\'s announcement on changing some special fund-raising accounts and re-signing the quadripartite supervisory agreement
Maiwei Biotech: Opinions of Haitong Securities Co., Ltd. on the matter of changing some special accounts for fund-raising and re-signing the quadripartite supervisory agreement
Maiwei Biotech: Announcement of Resolutions of the 13th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech: Maiwei Biotech Report for the Third Quarter of 2024
Maiwei Biotech\'s announcement on changing some special accounts for fund-raising and re-signing the quadripartite supervision agreement
Haitong Securities Co., Ltd. inspection opinions on the matter of Miwei (Shanghai) Biotechnology Co., Ltd. changing some special accounts for fund-raising and re-signing the quadripartite supervisory agreement
Announcement of Resolutions of the 13th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech Report for the Third Quarter of 2024
Maiwei Biotech Investor Relations Activity Record List (2024/09/01)
Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.
Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei Biotech
Haitong Securities Co., Ltd.\'s 2024 semi-annual follow-up report on the continuous supervision of Maiwei (Shanghai) Biotechnology Co., Ltd.
Maiwei Biotech 2024 Semi-Annual Report
Notice of Maiwei Biotech on convening the 3rd Extraordinary General Meeting of Shareholders in 2024
Maiwei Biotech\'s 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Summary of Maiwei Biotech\'s 2024 Semi-Annual Report
Announcement of Resolutions of the 12th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech\'s special report on the storage and actual use of funds raised in the 2024 semi-year
Maiwei Biotech 2024 3rd Extraordinary General Meeting of Shareholders Meeting Information
Mabwell: Meiwei Biotech voluntarily disclosed the announcement that the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has obtained approval from the CDE.
Analysis
Price Target
No Data
No Data